A Phase I, Randomized, Double-Blinded, Single-Dose Study Evaluating the Pharmacokinetic Equivalence of the Biosimilar IBI305 and Bevacizumab in Healthy Male Subjects
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS（2019）
Key words
biosimilar,phase I,IBI305,bevacizumab,pharmacokinetics
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined